Registry for patients with fibrotic interstitial lung disease in Taiwan

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational registry aims to evaluate the long-term outcomes of patients diagnosed with fibrotic interstitial lung disease (ILD) in Taiwan. It will collect comprehensive clinical data from multiple centers, including epidemiological information, comorbidities, and various tests such as pulmonary function tests and echocardiograms, all following a standardized protocol. Key components include annual high-resolution computed tomography (HRCT) scans and cardiopulmonary exercise tests (CPET), along with biobank blood samples. The registry seeks to answer critical questions regarding mortality differences among ILD patients and the effectiveness of anti-fibrotic drugs.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Aged over 18 years old.
2. Diagnosed as ILD by a pulmonologist, rheumatologist or radiologist
3. Various casue of ILD, including Idiopathic pulmonary fibrosis (IPF), Connective tissue disease-associated interstitial lung disease (CTD-ILD), Unclassifed ILD, drug-induced ILD, lymphangioleiomyomatosis (LAM), and sarcoidosis-associated ILD.

Exclusion Criteria:

1. Under 18 years of age.
2. Failure to express informed consent in person.

Where it's running

• Taichung Veterans General Hospital
  Taichung, Taiwan Recruiting

Study contacts

• Principal investigator: Pin-Kuei Fu, MD., Ph.D — Taichung Veterans General Hospital
• Study coordinator: Pin-Kuei Fu, MD., Ph.D
• Email: yetquen@gmail.com
• Phone: 04-23592525

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• See if 18F-FAPI-74 PET/CT can better detect fibrosis in heart and lung disease

  Researchers are testing a new PET/CT tracer, 18F-FAPI-74, to see if it can reveal early fibrotic changes in people with heart and lung diseases who are at risk for tissue scarring.

  Recruiting Phase 3 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07613099

• Using breath analysis to identify multiple lung diseases

  This study is testing if analyzing breath samples can help identify different lung diseases like lung cancer and COPD in a large group of 10,000 people.

  Recruiting ChromX Health · Guangzhou, Guangdong · NCT06528418

• Identifying lung disease signatures using advanced MRI techniques

  This study is testing a new MRI technique to see if it can help identify which patients with pulmonary hypertension might benefit from specific treatments.

  Recruiting Phase 2 Duke University · Durham, North Carolina · NCT04778046

• Telitacicept for primary Sjögren’s with interstitial lung disease

  This study tests whether Telitacicept helps people with primary Sjögren’s syndrome and interstitial lung disease compared with standard immunosuppressants.

  Recruiting Peking University People's Hospital · Beijing · NCT07843381

• Inhaled mosliciguat for pulmonary hypertension in interstitial lung disease (PH-ILD) patients

  This study tests inhaled mosliciguat versus placebo in people with PH-ILD to see if it helps with their condition.

  Recruiting at 3 sites Phase 3 Pulmovant, Inc. · Kissimmee, Florida and 2 other locations · NCT07816185

• Treprostinil Palmitil Inhalation Powder for Progressive Pulmonary Fibrosis

  A 52-week study will test whether once-daily Treprostinil Palmitil Inhalation Powder helps lung function in adults with progressive pulmonary fibrosis compared to placebo.

  Recruiting Phase 3 Insmed Incorporated · DuBois, Pennsylvania · NCT07805785

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.